PTGS2 and glioma: The treatment resulted in the increased expression of mRNA for IL-1β, IL-6, and IL-18 and decreased expression of mRNA for nitric oxide synthase 2 (NOS2) and prostaglandin-endoperoxide synthase 2 (PTGS2), arginase, and transforming growth factor beta (TGF-β), as well as insulin-like growth factor (IGF) in microglial cells, which suggests that Que may be considered as an adjuvant in the treatment of gliomas.